有效的抗癌药物5-化甲 ((IV) 前药物
Aleen Khoury1, Maria George Elias2, Jennette A Sakoff3
1School of Science, Western Sydney University, Penrith South, NSW 2751, Australia.
Journal of inorganic biochemistry
|November 30, 2025
概括
新的 ((IV) 预制药与5-甲 (5FU) 衍生物显示强大的抗癌活性. 复合物6是一种白金 (IV) 前药,对前列腺癌细胞具有高度有效性,性能优于西斯及其白金 (II) 前体.
科学领域:
- 药用化学 医学化学
- 纳米医学是一种纳米医学.
- 癌症生物学 癌症生物学
背景情况:
- 基于的化疗仍然是癌症治疗的基石,但耐药性和毒性限制了疗效.
- 开发新的 (IV) 前药物提供了一种战略,通过提高稳定性和有针对性的输送来克服这些局限性.
- 将5-甲 (5FU) 等细胞毒剂纳入白金支架可以产生协同作用的抗癌效应.
研究的目的:
- 为了合成和表征新的 (IV) 预制药,该预制药与5-甲 (5FU) 衍生物功能化.
- 为了评估这些 (IV) 复合物的体内细胞毒性和机械性途径,与癌症细胞系的小组进行对比.
- 为了比较 (IV) 前药的疗效与现有的基化疗药物,如西斯.
主要方法:
- 六个含有5FU-乙酸或5FU-甲基酸连接体的 (IV) 复合物的合成和完整表征.
- 在不同癌细胞系的体外细胞毒性测试中,确定半最大抑制度 (GI50).
- 机械研究涉及反应性氧物种 (ROS) 生产和癌细胞中线粒体膜潜力的评估.
主要成果:
- 所有合成的 (IV) 复合物都在体外表现出显著的细胞毒性.
- 复合物6 (Pt(IV) ((56Me2Phen)) ((1S,2S-二氨酸环素)) ((5FU-甲基布他诺酸)) ((OH))) ((NO3) 2) 对前列腺癌细胞具有异常强度,GI50为1nM.
- 复合物6的活性高达cisplatin的1400倍,并且比它的白金 (II) 前体更强大,5FU-甲基酸衍生物比5FU-乙酸类似物更有效.
- 机理学研究表明,复合物5和6诱导癌细胞中的氧化应激和线粒体功能障碍.
结论:
- 将5FU衍生物纳入白金 (IV) 前药物显著增强了抗癌功效,并引入了新的作用机制.
- (IV) 前药6是癌症治疗进一步发展的非常有前途的候选药,因为它具有卓越的疗效和有利的机械特性.
- 这些发现支持 (IV) 前药作为下一代癌症治疗策略的潜力,提供更好的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Prodrugs
3.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
3.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
576
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
576
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431


